Akebia Therapeutics Inc. (NASDAQ:AKBA) saw an upside of 4.27% to close Monday at $2.93 after adding $0.12 on the day. The 5-day average trading volume is 1,500,280 shares of the company’s common stock. It has gained $2.97 in the past week. An average of 1,796,055 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 2,239,182.
AKBA’s 1-month performance is 1.74% or $0.05 on its low of $2.70 reached on 09/16/21. The company’s shares have touched a 52-week low of $2.09 and high of $5.14, with the stock’s rally to the 52-week high happening on 02/08/21. YTD, AKBA has achieved 4.64% or $0.13. However, the current price is down -43.00%% from the 52-week high price.
A Backdoor Way To Profit From Today’s Crypto Bull Market
In any crypto bull market, there's a lot of money to be made.
But what if we told you the best opportunities are not cryptocurrencies themselves… but instead, simply crypto stocks?
This strategy is simply and ridiculously easy.
Here are 6 ways to gain exposure to crypto outside the norm. This is arguably the safest bet you can make.
On Aug 31, 42 days have gone by since the last insider trading activity for Akebia Therapeutics Inc. (AKBA). Burke Steven Keith (SVP, Chief Medical Officer) most recently sold 1,042 shares at $2.83 per share on Aug 31. This transaction cost the insider $2,949. Director, GILMAN STEVEN C, sold 4,567 shares at a price of $3.32 on Jun 07. Then, on Mar 01, CEO and President Butler John P. sold 49,990 shares at a price of $3.40 per share. This transaction amounted to $169,771.
Akebia Therapeutics Inc. (AKBA) has a trailing price-to-earnings (P/E) ratio of 34.65 for the broader industry and 32.24 for the sector.AKBA stock has a beta of 1.63. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 2.30 while the price-to-book (PB) in the most recent quarter is 2.71.
Akebia Therapeutics Inc.’s quick ratio for the period ended June 29 was 1.80, with the current ratio over the same period at 2.00 meaning that AKBA stock is able to fulfill its debt obligations. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.55, while the total debt to equity was 0.55. In terms of profitability, the gross margin trailing 12 months is 31.20%. The trailing 12-month EBITDA margin is -76.98%. The firm’s gross profit as reported stood at $114.93 million against revenue of $295.31 million.
For the quarterly period ending June 29 this year, Net income and sales went up compared to those figures reported in the previous quarter. Analysts expected AKBA to announce -$0.32 per share in earnings in its latest quarter, but it posted -$0.51, representing a -59.40% surprise. EBITDA for the quarter stood at more than -$69.84 million. AKBA stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 437.23 million, with total debt at $124.23 million. Shareholders hold equity totaling $174.54 million
Let’s look briefly at Akebia Therapeutics Inc. (AKBA) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 11 October was 58.51% to suggest the stock is trending Neutral, with historical volatility in this time period at 33.23%.
The stock’s 5-day moving average is $2.82, reflecting a +4.64% or $0.13 change from its current price. AKBA is currently trading +0.34% above its 20-day SMA, -14.08% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by +18.62% and -1.68% respectively.
Stochastic %K and %D was 35.04% and 24.44% and the average true range (ATR) pointed at 0.14. The RSI (14) points at 54.86%, while the 14-day stochastic is at 56.41% with the period’s ATR at 0.14. The stock’s 9-day MACD Oscillator is pointing at 0.02 and -0.01 on the 14-day charts.
In the most recent analyst report for Akebia Therapeutics Inc. (NASDAQ: AKBA), Cantor Fitzgerald launched coverage with an Overweight rating. Analysts offering their rating for AKBA stock have a consensus rating for the stock as Overweight. Currently, 1 brokerage advisors rate AKBA as a “sell,”, while 1 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 5 have offered a “buy” rating.
What is AKBA’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $2.76 and a high of $10.00, with their median price target at $6.50. Looking at these predictions, the average price target given by analysts is for Akebia Therapeutics Inc. (AKBA) stock is $6.63.